https://www.selleckchem.com/Bcl-2.html
The objective response rate (ORR) and progression-free survival (PFS) of anti-PD-1/PD-L1 therapy clearly differed according to the different TME types (ORR and PFS; type I 64%, 14.5 mo; type II 12%, 2.1 mo; type III 24%, 3.6 mo; type IV; 41%, 10.8 mo). In patients with PD-L1 tumors, type I tumors had significantly better ORR and PFS than type III tumors (ORR p 0.001 and PFS p 0.001). The presence of TP53 and KRAS mutation was related to the density of CD8-positive TILs and PD-L1 expression, respectively. Differential types of TME, includ
Like
Comment
Share
